Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Kurosky SK, Davis KL, Galindo CM. Effect of combination vaccines on hepatitis B vaccine compliance in children in the United States. Pediatr Infect Dis J. 2017 Jul;36(7):e189-96. doi: 10.1097/INF.0000000000001548
Abeysinghe S, Margulis AV, Mauskopf J, Ainsworth C. Risk factors for RSV hospitalization in healthy preterm infants: a meta-analysis. Letter to the editor. Pediatr Infect Dis J. 2017 Jul;36(7):696. doi: 10.1097/INF.0000000000001559
Mauskopf J, Margulis AV, Samuel M, Lohr KN. Respiratory syncytial virus hospitalizations in healthy preterm infants: systematic review. Pediatr Infect Dis J. 2016 Jul;35(7):e229-38. doi: 10.1097/INF.0000000000001163
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Phanikumar CV, Maitra B. Willingness-to-pay and preference heterogeneity for rural bus attributes. J Transp Eng A-Syst. 2007 Jan;133(1).